# Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)

> **NCT03809429** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 437 (actual)

## Conditions studied

- Infertility, Female

## Interventions

- **DRUG:** FE 999049 + GnRH agonist (GONAPEPTYL)
- **DRUG:** FE 999049 + GnRH antagonist (CETROTIDE)

## Key facts

- **NCT ID:** NCT03809429
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-29
- **Primary completion:** 2022-02-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809429, "Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03809429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*